{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:25:32Z","timestamp":1793316332203,"version":"4.5.0"},"reference-count":75,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma (LUAD) presenting with malignant pleural effusion (MPE) at diagnosis have a poor prognosis. Options are limited after EGFR-TKI resistance. Ivonescimab, a PD-1\/VEGFA bispecific antibody, is effective in advanced non-small cell lung cancer, but its efficacy in patients with baseline MPE and complex acquired resistance remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 55-year-old man was diagnosed with LUAD and significant MPE, featuring an EGFR exon 19 deletion and over 20 co-mutations. The patient eventually developed resistance to both first-line gefitinib and later almonertinib. Repeat genomic testing of pleural fluid upon progression revealed persistent alterations in 12 genes, including the original EGFR sensitizing mutation, TP53, AKT2, RARA, and SETD2, alongside newly acquired mutations in CHEK1, CUL3, DNMT1, HMCN1, and TBX3, and RB1 copy number loss, in the absence of typical resistance mechanisms such as T790M or MET amplification or histologic transformation to small cell lung cancer. PD-L1 expression on the effusion cell blocks was positive (TPS 40%, CPS 41). He received ivonescimab monotherapy, achieving disease control for nearly 5 months before transitioning to ivonescimab plus pemetrexed with continued benefit and a manageable safety profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case illustrates the potential benefit of ivonescimab in patients with EGFR-mutant LUAD and baseline MPE who develop complex, non-canonical resistance to EGFR-TKIs. These findings support further clinical evaluation of ivonescimab in this poor-prognosis subgroup and highlight the importance of repeated molecular profiling in guiding treatment strategy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1725067","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T06:36:55Z","timestamp":1765953415000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Ivonescimab in EGFR-mutant lung cancer with baseline malignant pleural effusion and acquired complex resistance"],"prefix":"10.3389","volume":"16","author":[{"given":"Zeming","family":"Mo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoya","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobin","family":"Jian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuju","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sisi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3390\/cancers17020255","article-title":"Recent advances in the clinical translation of small-cell lung cancer therapeutics","volume":"17","author":"Das","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.5334\/aogh.2419","article-title":"Global epidemiology of lung cancer","volume":"85","author":"Barta","year":"2019","journal-title":"Ann Glob Health"},{"key":"B5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-025-01679-1","article-title":"Recent advances in therapeutic strategies for non-small cell lung cancer","volume":"18","author":"Su","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12935-024-03211-w","article-title":"Immune modulation in Malignant pleural effusion: from microenvironment to therapeutic implications","volume":"24","author":"Ge","year":"2024","journal-title":"Cancer Cell Int"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/resp.12496","article-title":"Clinical features and survival of lung cancer patients with pleural effusions","volume":"20","author":"Porcel","year":"2015","journal-title":"Respirology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2010.136994","article-title":"Management of a Malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010","volume":"65","author":"Roberts","year":"2010","journal-title":"Thorax"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00069812","article-title":"Survival of lung adenocarcinoma patients with Malignant pleural effusion","volume":"41","author":"Wu","year":"2013","journal-title":"Eur Respir J"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-24-757","article-title":"EGFR mutations in patients with lung adenocarcinoma and Malignant pleural effusion: a propensity score-matched analysis of a single-center database","volume":"13","author":"Yang","year":"2024","journal-title":"Transl Lung Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1177\/0300060514539273","article-title":"Frequency of EGFR mutations in lung adenocarcinoma with Malignant pleural effusion: Implication of cancer biological behaviour regulated by EGFR mutation","volume":"42","author":"Zou","year":"2014","journal-title":"J Int Med Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-012-0078-4","article-title":"EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in Malignant pleural effusion of lung adenocarcinoma","volume":"35","author":"Smits","year":"2012","journal-title":"Cell Oncol (Dordr)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00195-8","article-title":"Overcoming therapy resistance in EGFR-mutant lung cancer","volume":"2","author":"Passaro","year":"2021","journal-title":"Nat Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41571-024-00971-2","article-title":"The changing treatment landscape of EGFR-mutant non-small-cell lung cancer","volume":"22","author":"Zhou","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16061","article-title":"Addition of bevacizumab for Malignant pleural effusion as the manifestation of acquired EGFR-TKI resistance in NSCLC patients","volume":"8","author":"Jiang","year":"2017","journal-title":"Oncotarget"},{"key":"B16","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s10637-019-00808-1","article-title":"Negative impact of Malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation","volume":"38","author":"Kawamura","year":"2020","journal-title":"Invest New Drugs"},{"key":"B17","doi-asserted-by":"publisher","first-page":"12071","DOI":"10.1038\/s41598-023-39211-5","article-title":"Efficacy of hyperthermic intrathoracic chemotherapy for initially diagnosed lung cancer with symptomatic Malignant pleural effusion","volume":"13","author":"Li","year":"2023","journal-title":"Sci Rep"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2019.09.36","article-title":"Intracavitary chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is not superior to TKI monotherapy in controlling Malignant pleural effusion recurrence in EGFR-mutated lung cancer patients","volume":"11","author":"Wang","year":"2019","journal-title":"J Thorac Dis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.21037\/atm-22-6101","article-title":"Efficacy and safety of original EGFR-TKI combined with bevacizumab in advanced lung adenocarcinoma patients harboring EGFR-mutation experiencing gradual progression after EGFR-TKI treatment: a single-arm study","volume":"10","author":"Long","year":"2022","journal-title":"Ann Transl Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/dc.25276","article-title":"The detection of PD-L1 expression on liquid-based cytology in pleural effusion of lung adenocarcinoma and its prognostic evaluation: Between paired liquid-based cytology and cell block samples","volume":"52","author":"Ma","year":"2024","journal-title":"Diagn Cytopathol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13004","article-title":"Malignant pleural effusion as a predictor of the efficacy of anti-PD-1 antibody in patients with non-small cell lung cancer","volume":"10","author":"Shibaki","year":"2019","journal-title":"Thorac Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2020.02.06","article-title":"PD-L1 expression in Malignant pleural effusion samples and its correlation with oncogene mutations in non-small cell lung cancer","volume":"12","author":"Song","year":"2020","journal-title":"J Thorac Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251338046","article-title":"Efficacy and safety of distinct regimens for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review and network meta-analysis","volume":"17","author":"Zhang","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02073-w","article-title":"Ivonescimab: first approval","volume":"84","author":"Dhillon","year":"2024","journal-title":"Drugs"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)02722-3","article-title":"Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China","volume":"405","author":"Xiong","year":"2025","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.10.034","article-title":"PD-L1 expression of tumor cells, macrophages, and immune cells in non-small cell lung cancer patients with Malignant pleural effusion","volume":"13","author":"Tseng","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"70","DOI":"10.25259\/Cytojournal_59_2024","article-title":"Expression and clinical significance of programmed death ligand-1 evaluated by 22C3 antibody in pleural effusion metastatic non-small-cell lung cancer","volume":"21","author":"Gu","year":"2024","journal-title":"Cytojournal"},{"key":"B28","doi-asserted-by":"publisher","first-page":"11206","DOI":"10.1038\/s41598-018-29156-5","article-title":"PD-L1 expression in pleural effusions of pulmonary adenocarcinoma and survival prediction: a controlled study by pleural biopsy","volume":"8","author":"Xu","year":"2018","journal-title":"Sci Rep"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2008.12.007","article-title":"Angiogenetic biomarkers in non-small cell lung cancer with Malignant pleural effusion: correlations with patient survival and pleural effusion control","volume":"65","author":"Hsu","year":"2009","journal-title":"Lung Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.canlet.2020.06.014","article-title":"Platelet factor 4 regulates T cell effector functions in Malignant pleural effusions","volume":"491","author":"Mulet","year":"2020","journal-title":"Cancer Lett"},{"key":"B31","article-title":"The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in Malignant effusions","volume":"29","author":"Wada","year":"2009","journal-title":"Anticancer Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/1759-7714.13238","article-title":"A randomized clinical study to compare intrapleural infusion with intravenous infusion of bevacizumab in the management of Malignant pleural effusion in patients with non-small-cell lung cancer","volume":"11","author":"Nie","year":"2020","journal-title":"Thorac Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s12957-025-03887-y","article-title":"Intracavitary perfusion with bevacizumab plus cisplatin versus cisplatin alone for Malignant pleural effusion in lung cancer patients: a meta-analysis of randomized controlled trials","volume":"23","author":"Han","year":"2025","journal-title":"World J Surg Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100424","article-title":"Osimertinib and bevacizumab cotreatment for untreated EGFR-mutated NSCLC with Malignant pleural or pericardial effusion (SPIRAL II): A single-arm, open-label, phase 2 clinical trial","volume":"3","author":"Hibino","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.7314\/apjcp.2014.15.19.8435","article-title":"Prognostic values of VEGF and endostatin with Malignant pleural effusions in patients with lung cancer","volume":"15","author":"Zhang","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e53449","DOI":"10.1371\/journal.pone.0053449","article-title":"Recombinant human endostatin endostar suppresses angiogenesis and lymphangiogenesis of Malignant pleural effusion in mice","volume":"7","author":"Ma","year":"2012","journal-title":"PloS One"},{"key":"B37","article-title":"Randomized controlled trial of endostar combined with cisplatin\/pemetrexed chemotherapy for elderly patients with advanced Malignant pleural effusion of lung adenocarcinoma","volume":"23","author":"Jie Wang","year":"2018","journal-title":"J buon"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.649999","article-title":"Intrapleural administration with rh-endostatin and chemical irritants in the control of Malignant pleural effusion: A systematic review and meta-analysis","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e32207","DOI":"10.1097\/md.0000000000032207","article-title":"Efficacy and safety of endostar combined with cisplatin in treatment of non-small cell lung cancer with Malignant pleural effusion: A meta-analysis","volume":"101","author":"Hu","year":"2022","journal-title":"Med (Baltimore)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.01891","article-title":"Randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR- or ALK-mutated non-small-cell lung cancer (ATTLAS, KCSG-LU19-04)","volume":"42","author":"Park","year":"2024","journal-title":"J Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.ccell.2021.07.005","article-title":"Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study","volume":"39","author":"Zhou","year":"2021","journal-title":"Cancer Cell"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14214","article-title":"Efficacy and safety of bevacizumab combined with EGFR-TKIs in advanced non-small cell lung cancer: A meta-analysis","volume":"13","author":"Yang","year":"2022","journal-title":"Thorac Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.07.009","article-title":"IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC","volume":"16","author":"Socinski","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/s2213-2600(19)30084-0","article-title":"Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial","volume":"7","author":"Reck","year":"2019","journal-title":"Lancet Respir Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108109","article-title":"First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial","volume":"201","author":"Lee","year":"2025","journal-title":"Lung Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-24-347","article-title":"Utility of atezolizumab plus bevacizumab, carboplatin, and paclitaxel combination for the treatment of advanced non-squamous non-small cell lung cancer patients with Malignant pleural effusion","volume":"13","author":"Hisakane","year":"2024","journal-title":"Transl Lung Cancer Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03658-y","article-title":"Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial","volume":"31","author":"Zhou","year":"2025","journal-title":"Nat Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(23)00135-2","article-title":"Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"11","author":"Lu","year":"2023","journal-title":"Lancet Respir Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-SITC2025.1348","article-title":"1348 Final overall survival analysis of HARMONi-A study comparing ivonescimab plus chemotherapy to chemotherapy alone in patients with EGFR+ NSCLC progressed on EGFR-TKI treatment","volume":"13","author":"Zhang","year":"2025","journal-title":"J ImmunoTherapy Cancer"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.10613","article-title":"Ivonescimab plus chemotherapy in non-small cell lung cancer with EGFR variant: A randomized clinical trial","volume":"332","author":"Fang","year":"2024","journal-title":"Jama"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/resp.13614","article-title":"PD-L1 detection in histology specimens and matched pleural fluid cell blocks of patients with NSCLC","volume":"24","author":"Grosu","year":"2019","journal-title":"Respirology"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e2400907","DOI":"10.1200\/po-24-00907","article-title":"Immune checkpoint inhibitors in epidermal growth factor receptor-tyrosine kinase inhibitor-resistant chemotherapy-na\u00efve advanced non-small cell lung cancer: A meta-analysis based on eight randomized trials","volume":"9","author":"Huang","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkac1000","article-title":"The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest","volume":"51","author":"Szklarczyk","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.05.018","article-title":"Comparative study of EGFR mutations detected in Malignant pleural effusion, plasma and tumor tissue in patients with adenocarcinoma of the lung","volume":"135","author":"Wang","year":"2019","journal-title":"Lung Cancer"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.04.030","article-title":"Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial","volume":"43","author":"Zhang","year":"2019","journal-title":"EBioMedicine"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.9104","article-title":"Association of alterations in multiple tumor suppressor genes with poor outcomes in patients with EGFR-mutant lung cancer","volume":"41","author":"Stockhammer","year":"2023","journal-title":"J Clin Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-025-04054-0","article-title":"Baseline retinoblastoma transcriptional corepressor 1 (Rb1) functional inactivation is a pre-requisite but not sufficient for small-cell histological transformation in epidermal growth factor receptor (EGFR) mutant lung adenocarcinomas post-tyrosine kinase inhibitor therapy","volume":"487","author":"Nambirajan","year":"2025","journal-title":"Virchows Arch"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-23-0816","article-title":"Analysis and visualization of longitudinal genomic and clinical data from the AACR project GENIE biopharma collaborative in cBioPortal","volume":"83","author":"de Bruijn","year":"2023","journal-title":"Cancer Res"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e15523","DOI":"10.1111\/1759-7714.15523","article-title":"EGFR, TP53, and CUL3 triple mutation in non-small cell lung cancer and its potentially poor prognosis: A case report and database analysis","volume":"16","author":"Hatano","year":"2025","journal-title":"Thorac Cancer"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.75963","article-title":"Acquired resistance to EGFR-TKIs in NSCLC mediates epigenetic downregulation of MUC17 by facilitating NF-\u03baB activity via UHRF1\/DNMT1 complex","volume":"19","author":"Lin","year":"2023","journal-title":"Int J Biol Sci"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2025.117280","article-title":"EGFR tyrosine kinase inhibitor ZZC4 overcomes acquired resistance to gefitinib","volume":"497","author":"Attiogbe","year":"2025","journal-title":"Toxicol Appl Pharmacol"},{"key":"B62","first-page":"4989","article-title":"Whole Exome Sequencing reveals clinically important pathogenic mutations in DNA repair genes across lung cancer patients","volume":"13","author":"Wang","year":"2023","journal-title":"Am J Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.Mcr-14-0674-t","article-title":"Transposon mutagenesis screen identifies potential lung cancer drivers and CUL3 as a tumor suppressor","volume":"13","author":"Dorr","year":"2015","journal-title":"Mol Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252312585","article-title":"Exploring aerobic energy metabolism in breast cancer: A mutational profile of glycolysis and oxidative phosphorylation","volume":"25","author":"Oliveira","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.3390\/genes13071282","article-title":"Comprehensive analysis of HMCN1 somatic mutation in clear cell renal cell carcinoma","volume":"13","author":"Gong","year":"2022","journal-title":"Genes (Basel)"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2019.144223","article-title":"The roles and regulation of TBX3 in development and disease","volume":"726","author":"Khan","year":"2020","journal-title":"Gene"},{"key":"B67","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41698-024-00797-2","article-title":"Longitudinal genomic profiling using liquid biopsies in metastatic nonsquamous NSCLC following first line immunotherapy","volume":"9","author":"Ding","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-14-2305","article-title":"VEGF-A expression correlates with TP53 mutations in non-small cell lung cancer: implications for antiangiogenesis therapy","volume":"75","author":"Schwaederl\u00e9","year":"2015","journal-title":"Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.02.005","article-title":"Programmed cell death-ligand 1 (PD-L1) expression is associated with RAS\/TP53 mutations in lung adenocarcinoma","volume":"118","author":"Serra","year":"2018","journal-title":"Lung Cancer"},{"key":"B70","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.cllc.2021.08.009","article-title":"PD-L1 expression and comprehensive molecular profiling predict survival in nonsmall cell lung cancer: A real-world study of a large chinese cohort","volume":"23","author":"Jin","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-019-0733-6","article-title":"Base excision repair regulates PD-L1 expression in cancer cells","volume":"38","author":"Permata","year":"2019","journal-title":"Oncogene"},{"key":"B72","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13578-020-00499-9","article-title":"KLHL18 inhibits the proliferation, migration, and invasion of non-small cell lung cancer by inhibiting PI3K\/PD-L1 axis activity","volume":"10","author":"Jiang","year":"2020","journal-title":"Cell Biosci"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217616","article-title":"Clinical development of immuno-oncology therapeutics","volume":"617","author":"Wang","year":"2025","journal-title":"Cancer Lett"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2503001","article-title":"Overall survival with amivantamab-lazertinib in EGFR-mutated advanced NSCLC","volume":"393","author":"Yang","year":"2025","journal-title":"N Engl J Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1485358","article-title":"Case report: Therapeutic response of front-line cadonilimab plus chemotherapy on patient with advanced lung adenocarcinoma harboring STK11 genetic aberration","volume":"15","author":"Feng","year":"2024","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1725067\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T06:37:19Z","timestamp":1765953439000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1725067\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":75,"alternative-id":["10.3389\/fimmu.2025.1725067"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1725067","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"article-number":"1725067"}}